Pyxis Oncology, Inc.

NasdaqGS:PYXS Aktierapport

Börsvärde: US$137.5m

Pyxis Oncology Förvaltning

Förvaltning kriterier kontrolleras 3/4

Pyxis Oncology VD är Tom Civik, utsedd i Feb 2026, har en anställningstid på mindre än ett år. äger direkt 0.35% av företagets aktier, värda $ 481.49K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 1.3 år respektive 4.8 år.

Viktig information

Tom Civik

Verkställande direktör

US$75.9k

Total ersättning

VD-lön i procentn/a
Anställning som VDless than a year
Ägande av VD0.4%
Ledningens genomsnittliga anställningstid1.3yrs
Styrelsens genomsnittliga mandatperiod4.8yrs

Senaste uppdateringar av ledningen

Recent updates

Seeking Alpha • Sep 12

Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade)

Summary PYXS is developing micvotabart pelidotin for head and neck squamous cell carcinoma, with key clinical readouts expected in H2'25 and H1'26. While micvotabart pelidotin has shown early efficacy and tolerability, limited patient data and competition raise concerns. PYXS has cash runway into H2'26 but faces risk from potential clinical disappointments, competitor updates, and possible dilutive fundraising. Read the full article on Seeking Alpha
Analysartikel • Jun 19

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Dec 07

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Summary Pyxis Oncology's lead candidate, PYX-201, showed promising response rates in Phase 1 trials but raised safety concerns due to a patient's death. The company’s valuation appears deeply discounted, with a P/B ratio of 0.7 compared to a sector median of 2.4, reflecting market pessimism. PYX-201's ongoing trials and upcoming catalysts in 2025-2026 are crucial for addressing safety concerns and demonstrating efficacy across multiple cancer types. Investors should consider PYXS's financial runway, speculative nature, and potential for significant stock appreciation if future trial results are favorable. Despite setbacks, PYXS's valuation appears deeply oversold, presenting a speculative "Buy" opportunity due to its robust pipeline and potential revenue from licensing. Read the full article on Seeking Alpha
Seeking Alpha • Sep 13

Moment Of Truth Approaches For Pyxis Oncology

Summary Pyxis Oncology is an antibody and antibody-drug conjugate developer with initial results from two clinical trials ahead in 2024. Data from a phase 1 study of PYX-201, an ADC targeting extra domain B of fibronectin, in multiple tumor types, are expected in fall 2024. Data from a phase 1 study of PYX-106, an anti-Siglec-15 antibody, in multiple tumor types, are expected by year-end 2024. PYXS estimates its current cash will last until H2'26. Read the full article on Seeking Alpha
Seeking Alpha • Jun 10

Pyxis Oncology: Promising Research Amid Cash Constraints

Summary Pyxis Oncology develops innovative therapeutics for hard-to-treat cancers using antibody-drug conjugates and immunotherapies. The company's pipeline includes PYX-201 and PYX-106, targeting multiple solid tumor types, with preliminary data expected in 2024. Pyxis recently announced a workforce reduction and sold the royalties and commercialization rights of Beovu to extend its cash runway. Despite innovative technology, PYXS faces financial constraints and early-stage development risks. A neutral stance on PYXS is prudent due to speculative IP and potential shareholder dilution. Read the full article on Seeking Alpha
Seeking Alpha • Mar 28

Pyxis Oncology: Data Arriving Later Than Expected, But May Be Worth The Wait

Summary Pyxis Oncology is developing antibodies and antibody-drug conjugates for various tumor types. Initial data from the phase 1 trials of PYX-106 and PYX-201 are now expected in H2'24 and fall 2024 respectively. PYXS raised $50M in gross proceeds with a private placement in February 2024 and is cashed into H2'26. Read the full article on Seeking Alpha
Seeking Alpha • Jan 18

Pyxis Oncology: Making A Bold Acquisition Move, But It's Not A Convincing Thesis

Summary Pyxis Oncology is a biotech company focused on developing immunotherapies for cancer treatment. Their most advanced pipeline project is sotigalimab, a CD40 agonist, which has shown promising results in melanoma and liposarcoma. The company has enough funds to continue operating for 5-6 quarters, but future funding may require dilutive financing. Read the full article on Seeking Alpha
Analysartikel • Feb 18

Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysartikel • Sep 01

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 15

Pyxis Oncology GAAP EPS of -$0.79 beats by $0.06

Pyxis Oncology press release (NASDAQ:PYXS): Q2 GAAP EPS of -$0.79 beats by $0.06. Pyxis Oncology had cash and cash equivalents of $223 million as of June 30, 2022, and approximately $207 million (preliminary, unaudited) as of August 15, 2022, which is expected to fund operations through the second half of 2024.
Analysartikel • Apr 13

We're Hopeful That Pyxis Oncology (NASDAQ:PYXS) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

VD OCH KONCERNCHEF

Tom Civik (57 yo)

less than a year
Anställning
US$75,904
Kompensation

Mr. Thomas Civik, also known as Tom, is Independent Chairman of the Board at ImCheck Therapeutics SAS since March 2023. He is Interim CEO & Director of Pyxis Oncology, Inc. from February 3, 2026. He was In...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Thomas Civik
Interim CEO & Directorless than a yearUS$75.90k0.35%
$ 481.5k
Jitendra Wadhane
Chief Accounting Officer4.8yrsUS$766.75k0.51%
$ 698.7k
Balu Balasubramanian
Interim Chief Technology Officer4.4yrsinga uppgifteringa uppgifter
Donna Regalado
Head of Human Resources1.4yrsinga uppgifteringa uppgifter
Charles Gombar
Senior Vice President of Portfolio & Program Management4.4yrsinga uppgifteringa uppgifter
Michael Bui
Senior Vice President of Global Regulatory Affairs1.3yrsinga uppgifteringa uppgifter
Supriya Roth
Head of Commercial Development1.3yrsinga uppgifteringa uppgifter
Shui He
Head of Biometrics1.3yrsinga uppgifteringa uppgifter
Hongwei Wang
Head of ADC Development & Clinical Strategy1.3yrsinga uppgifteringa uppgifter
Marsha Crochiere
Head of Translational Medicine & Research1.3yrsinga uppgifteringa uppgifter
Chris Cohen
Head of Drug Safety & Pharmacovigilance1.4yrsinga uppgifteringa uppgifter
Stan Szpindor
Head of R&D Quality1.4yrsinga uppgifteringa uppgifter
1.3yrs
Genomsnittlig anställningstid

Erfaren ledning: PYXS s ledningsgrupp anses inte vara erfaren ( 1.3 års genomsnittlig anställningstid), vilket föreslår ett nytt team.

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Thomas Civik
Interim CEO & Director4.8yrsUS$75.90k0.35%
$ 481.5k
John Flavin
Independent Chairman7.1yrsUS$155.90k0.65%
$ 896.2k
Anthony Tolcher
Member of Clinical & Translational Medicine Advisory Board5yrsinga uppgifteringa uppgifter
Freda Lewis-Hall
Independent Director4.8yrsUS$73.40k0.38%
$ 523.8k
Darren Cline
Independent Director4.8yrsUS$83.40k0.40%
$ 545.6k
Santhosh Palani
Independent Director2.3yrsUS$127.78k0%
$ 0
Jason J. Luke
Member of Clinical & Translational Medicine Advisory Boardno datainga uppgifteringa uppgifter
Christopher O'Donnell
Member of Technical Advisory Board4.2yrsinga uppgifteringa uppgifter
Morris Rosenberg
Chairperson of Technical Advisory Boardno datainga uppgifteringa uppgifter
Robert Baffi
Member of Technical Advisory Boardno datainga uppgifteringa uppgifter
Virgil Lawlis
Member of Technical Advisory Boardno datainga uppgifteringa uppgifter
Michael Sun
Member of Technical Advisory Boardno datainga uppgifteringa uppgifter
4.8yrs
Genomsnittlig anställningstid
56.5yo
Genomsnittlig ålder

Erfaren styrelse: PYXS s styrelse anses vara erfaren ( 4.8 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/06/25 10:06
Aktiekurs vid dagens slut2026/06/25 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Pyxis Oncology, Inc. bevakas av 13 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Tazeen AhmadBofA Global Research
Bradley CaninoGuggenheim Securities, LLC
Swayampakula RamakanthH.C. Wainwright & Co.